Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
12 drugs for “Carcinoma, Non-Small Cell Lung”
Approved 6
- CapmatinibNOVARTIS AGCarcinoma, Non-Small-Cell Lung
- CemiplimabREGENERON PHARMACEUTICALS, INC.Carcinoma，Non-Small-Cell Lung
- LorlatinibPFIZER INCCarcinoma, Non-Small-Cell Lung
- OsimertinibASTRAZENECA PLCCarcinoma, Non-Small-Cell Lung
- RepotrectinibBRISTOL MYERS SQUIBB COCarcinoma, Non-Small-Cell Lung
- SelpercatinibELI LILLY & CoCarcinoma, Non-Small-Cell Lung
Phase 3 6
- Gemcitabine aloneMAIA Biotechnology, Inc.Carcinoma, Non-Small -Cell Lung
- Intismeran autogeneMerck & Co., Inc.Carcinoma, Non-Small-Cell Lung
- LY3537982ELI LILLY & CoCarcinoma, Non-Small-Cell Lung
- OlomorasibELI LILLY & CoCarcinoma, Non-Small-Cell Lung
- RilvegostomigASTRAZENECA PLCCarcinoma, Non-Small Cell Lung
- Sigvotatug vedotinPFIZER INCCarcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small-Cell Lung (NSCLC)
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.